PLRX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Pliant Therapeutics Inc (PLRX) is not a good buy for a beginner investor with a long-term strategy at this time. The stock shows bearish technical indicators, weak financial performance, and lacks strong positive catalysts. While hedge funds are buying, the overall sentiment and data do not support a compelling long-term investment case.
The stock is showing bearish technical indicators. The MACD is negative and expanding, RSI is neutral at 33.89, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The current price is near the support level of 1.243, but there is no clear upward momentum.
Hedge funds are increasing their buying activity, with a 138.46% increase in the last quarter. Management has sufficient cash to fund operations into 2H28, providing operational stability.
Bearish technical indicators, weak financial performance with significant YoY declines in Net Income (-52.59%) and EPS (-53.66%), and no recent news or congress trading data to act as a catalyst. Analysts have lowered price targets to $3, indicating limited upside potential.
In Q4 2025, the company reported no revenue growth (0% YoY), a significant drop in Net Income (-52.59% YoY), and a decline in EPS (-53.66% YoY). Gross Margin remained at 0%. Overall, the financial performance is weak.
Analysts have lowered price targets from $4 to $3. Canaccord maintains a Hold rating, while Piper Sandler keeps an Overweight rating but acknowledges the stock's challenges and long development timelines for its pipeline.
